Abstract
Objective
To evaluate the efficacy of ifosfamide and etoposide (VP-16) in patients with small cell lung cancer (SCLC), and investigate the correlation between microvessel count (MVC) in tumor and chemotherapeutic sensitivity.
Methods
Forty-one consecutive cases of SCLC received chemotherapy of ifosfamide plus VP-16, and underwent investigation retrospectively. Immunohistochemistry using anti-human blood type H monoclonal antibody was conducted and MVC was recorded under light microscope.
Results
There were 27 limited-disease and 14 extensive-disease patients. The overall response rate was 92.7% (38/41) with 28 cases (68.3%) of complete response (CR), 10 (24.4%) with partial response (PR), 3 (7.3%) with progressive disease (PD). The 1-, 2-, 3-, and 5-year survival rates were 68.3% (28/41), 48.3% (20/41), 23.7% (9/38) and 11.1% (3/27), respectively, with the median survival of 26.8 months. The principal toxicities were grade 3–4 neutropenia in 8 cases (19.5%), grade 3–4 thrombocytopenia in 6 cases (14.6%), mild liver toxicity in 7 cases (17.0%) and mild renal function damage in 4 cases (9.8%). The mesenchymal vasculature was clearly visualized, with the mean value of 34.7 under each high microscopic power field. Of SCLC with more MVC (n=26), CR accounted for 84.6%; while in cancers with less MVC (n=15), CR took up 40.0%, with significant difference (P<0.05).
Conclusion
Administrating ifosfamide and VP-16 is in accordance with the biological features of SCLC and results in beneficial results as well as acceptable side effects. The MVC is positively correlated with the chemotherapeutic sensitivity, and serves as a vital factor contributing to chemosensitivity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Simon GR, Wagner H, American College of Chest Physicians. Small cell lung cancer[J]. Chest 2003; 123(1 Suppl): 259S–71S.
Ihde DC. Chemotherapy of lung cancer[J]. N Engl J Med 1992; 327:1434–41.
Hansen HH. Management of small-cell cancer of the lung[J]. Lancet. 1992; 339:846–9.
Li Y, Yang GY, Li HW, et al. The significance of anti-blood type H monoclonal antibody for the detection of interstitial vessels in lung cancer[J]. J Chin Med Univ 1992; 21:453–4.
Weidner N, Folkman J. Tumoral vascularity as a prognostic factor in cancer. In: DeVita Jr VT, Hellman S, Rosemberg SA, editors. Important advances in oncology[M]. Philadelphia, PA: Lippincot-Raven, 1996; p167–90.
Sandler AB. Chemotherapy for small cell lung cancer[J]. Semi Oncol 2003; 30:9–25.
Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment[J]. Cancer 1981; 47: 207–14.
Lucci M, Mussi A, Chella A, et al. Surgery in the management of small cell lung cancer[J]. Eur J Cardiothorac Surg 1997; 12:689–93.
Einhorn LH, Crawford J, Birch R, et al. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer[J]. J Clin Oncol 1988; 6:451–6.
Blackstein ME. Advances in chemotherapy for small cell lung cancer[J]. Semin Oncol 1994; 21(suppl 11): 38S–42S.
Glisson B, Scott C, Komaki R, et al. Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: Results of Radiation Therapy Oncology Group trial 93-12[J]. J Clin Oncol 2000; 18:2990–5.
Arriagada R, Le Chevalier T, Pignon JP, et al. Initial chemotherapeutic doses and survival in patients with limited small cell lung cancer[J]. N Engl J Med 1993; 329:1848–52.
Stupp R, Monnerat C, Turrisi AT 3rd, et al. Small cell lung cancer: state of the art and future perspectives[J]. Lung Cancer 2004; 45:105–17.
Fontanini G, Lucchi M, Vignati S, et al. Angiogenesis as a prognosis indicator of survival in non-small cell lung carcinoma: a prospective study[J]. J Natl Cancer Inst 1997; 89: 881–6.
Lucci M, Mussi A, Fontanini G, et al. Small cell lung carcinoma (SCLC): the angiogenic phenomenon[J]. Eur J Cardiothorac Surg 2002; 21:1105–10.
Author information
Authors and Affiliations
Corresponding author
Additional information
Foundation item: This work was supported by a grant from the Education Department of P.R.China (No. 2004[527]).
Biography: WANG Si-wen(1959–), female, associate professor, Fourth Hospital, China Medical University, majors in basic and clinical research on lung cancer.
Rights and permissions
About this article
Cite this article
Wang, Sw., Liu, Hx. & Li, Y. Efficacy of ifosfamide and VP-16 (etoposide) in patients with small cell lung cancer and the correlation between microvessel count on chemosensitivity. Chin. J. Cancer Res. 18, 116–120 (2006). https://doi.org/10.1007/s11670-006-0116-8
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11670-006-0116-8